EVIDENCE, IDENTITY & CONTEXT
THCP vs THC: differences, potency and evidence
THCP versus THC is often reduced to a striking number. That shortcut combines chemistry, laboratory findings and human experience as though they were interchangeable. A useful comparison asks separate questions: which molecule was examined, what was measured and how far the finding can reasonably be extended to a real product.

THCP evidence is mainly preclinical; no validated human potency conversion is established.
How we assess sources ↗The chemical difference behind the comparison
THCP stands for tetrahydrocannabiphorol. The research identifying it in cannabis described a seven-carbon side chain, compared with the five-carbon chain of delta-9 THC. Researchers also examined receptor binding and responses in mice. These chemical and preclinical findings were not a controlled comparison of intoxication in people. [1]
The similar names explain why the compounds are discussed together, but they do not make their effects interchangeable. An additional letter may represent an important structural difference. Matching a scientific paper to a label also requires checking the isomer: simply writing THC or THCP leaves part of the substance's identity unresolved.
| Identity | THCP | Delta-9 THC |
|---|---|---|
| Side chain | Seven carbons | Five carbons |
| Main question | Interpreting preclinical findings | Defining the human comparison |
| Human equivalence | Not established here | Not an automatic conversion |
What the famous «33 times» figure actually describes
The figure comes from a comparison of CB1 binding affinity. It describes the interaction observed in a particular receptor assay. It does not mean that a person experiences thirty-three times the effect, and it does not establish an exchange rate between quantities of commercial products. [1]
Binding affinity, receptor activation and clinical outcomes are different questions. A molecular interaction can be measured without knowing how much compound reaches a relevant tissue, which metabolites appear or how a human function changes. Turning the assay result directly into an intensity slogan removes the very variables that remain to be investigated.
How to read a claim about potency
Before accepting the phrase «more potent», identify the measured outcome. Researchers might examine receptor binding, cellular signalling, animal behaviour, subjective ratings or psychomotor performance. Even if every paper used the word potency, the studies would not necessarily be describing the same property.
A fair comparison retains the experimental system and the reference substance. Placing one number from a paper beside another published years later is insufficient: differences in methods, cells, conditions and composition may change the result. Commercial tables that erase these details suggest a level of precision their evidence cannot support.
What is known about human effects
The sources assembled here do not establish a reliable THCP-versus-THC human effects curve. This does not mean that THCP is inactive. It means that the evidence needed to quantify the comparison is missing. Pharmacological expectations should remain separate from demonstrated clinical outcomes.
Personal accounts can describe an experience, but usually cannot independently verify the product, its full composition or other exposures. An effect attributed to «THCP» may involve a mixture. Such accounts can raise surveillance questions; they cannot answer a question of equivalence that requires controlled research with adequately characterised substances.
The product may matter more than the headline
An investigation of seized products documented varied semi-synthetic cannabinoids and compositions. The sample does not represent the whole market, but it illustrates why an external name and an analytical result are different levels of information. [2]
An isolated percentage on a label does not explain which substances accompany the highlighted ingredient. Nor does it confirm that an available certificate concerns the particular batch being discussed. Comparing two packages by their largest printed name may therefore be less informative than examining two complete analytical reports, including the limits of what each actually tested.
Risk: uncertainty does not establish safety
The absence of human equivalence data prevents THCP from being described as a predictable version of THC. It also prevents claims that a chemical modification makes it cleaner or safer. A molecule can be precisely identified while major questions remain about interactions, repeated exposure and vulnerable populations.
Those gaps should not be converted into a list of inevitable outcomes. A more accurate statement is specific: this comparison establishes no safety margin, validates no therapeutic use and supports no substitution recommendation. European monitoring provides market and public-health context, but does not replace research specifically examining THCP. [3]
Legal status requires a full name and a jurisdiction
For Spain, the relevant official reference is Order SND/380/2025 and the control framework it amends. THCP derivatives must be checked under their full names; the description «hemp-derived» is not a legal assessment. [4]
Other countries require their own current official sources. Writing a page in English does not make a Spanish conclusion international. Questions about a substance, a medicine, a food and a particular marketed product are also distinct. Milnubes' Spanish legal framework guide explains those boundaries and links the applicable sources without treating a chemical comparison as legal clearance.
Two headlines built around one number
Imagine two headlines based on a binding assay. One reports greater affinity; the other promises a much more intense experience. The first preserves the measured finding, while the second adds a human prediction. The issue is not whether the number was copied accurately. It is whether the conclusion remains within the experimental question.
When reviewing a story, follow the subject of each sentence. If it begins with a receptor and ends with a person without explaining which human study connects them, the evidence has been extended. Recognising that gap allows the scientific observation to be retained without accepting its commercial expansion as an established outcome.
What would make a future comparison convincing?
Researchers would need characterised substances, a clearly defined outcome and an appropriate human study design with safety follow-up. Results should report uncertainty, sample size and limitations, rather than presenting only the most striking statistically significant difference. Independent replication would help distinguish a robust finding from a result limited to one setting.
Until that evidence bridge exists, the useful conclusion remains documentary: THCP and THC are related molecules, but current evidence offers no universal human multiplier. Keeping that distinction makes it possible to read new publications and changing product labels without turning every molecular observation into a promise about real experiences.
Frequently asked questions
Is THCP exactly thirty-three times stronger than THC?
No. The figure describes a CB1 binding result, not a human intoxication equivalence. It cannot be used to calculate substitutions between products.
Does stronger binding imply greater medical benefit?
No. Benefit must be demonstrated for a particular intervention and clinical condition. Receptor interaction alone establishes neither therapeutic usefulness nor tolerability or safety.
Are THCP-O and THCP the same?
No. THCP-O generally refers to a THCP acetate. A commercial abbreviation requires verification, and findings about THCP do not automatically apply to that derivative.
What is commonly missing from a commercial comparison?
Exact identity, batch composition, analytical methods, the outcome being compared and the limitations of the sources. Without those elements, an intensity ranking is not a scientific comparison.
Sources and scope
- Citti et al. (2019): THCP identification, receptor affinity and animal modelsPreclinical research
- Analysis of 80 seized semi-synthetic cannabinoid products (2025)Forensic analysis
- EUDA: European Drug Report 2026, new psychoactive substancesOfficial body
- BOE: Spanish Order SND/380/2025, additions to list IISpanish regulation
Documentary review with AI assistance; no independent clinical review. Educational information, not medical or legal advice. A chemical name does not establish the composition or safety of a commercial product.